Last reviewed · How we verify

NCT06380062

Choline Metabolites in People With Prostate Cancer and Those With Benign Hyperplasia

Completed Last updated 25 April 2024
What this trial tests

trial testing Plasma concentration of choline in Primary Prostate Urothelial Cancer in 350 participants. Completed in 30 November 2015.

Timeline
12 January 2012
Primary endpoint
30 November 2015
30 November 2015

Quick facts

Lead sponsorUniversität des Saarlandes
StatusCompleted
Study typeOBSERVATIONAL
Enrollment350
Start date12 January 2012
Primary completion30 November 2015
Estimated completion30 November 2015
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Universität des Saarlandes — full company profile →

Who can join

50 and older, male only, with Primary Prostate Urothelial Cancer or Benign Prostatic Hyperplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study was to investigate plasma concentrations of one-carbon metabolites and phospholipid classes in participants with primary prostate cancer and those with benign hyperplasia. Moreover, the metabolites were studied in relation to tumor grade and age.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Universität des Saarlandes trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06380062.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing